SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/06/20 Iovance Biotherapeutics, Inc. 10-Q 6/30/20 63:7.7M Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 1.27M 2: EX-10.3 Material Contract HTML 38K 3: EX-10.4 Material Contract HTML 51K 4: EX-31.1 Certification -- §302 - SOA'02 HTML 23K 5: EX-31.2 Certification -- §302 - SOA'02 HTML 23K 6: EX-32.1 Certification -- §906 - SOA'02 HTML 20K 7: EX-32.2 Certification -- §906 - SOA'02 HTML 20K 14: R1 Document And Entity Information HTML 71K 15: R2 Condensed Consolidated Balance Sheets HTML 90K 16: R3 Condensed Consolidated Balance Sheets HTML 40K (Parenthetical) 17: R4 Condensed Consolidated Statements of Operations HTML 40K 18: R5 Condensed Consolidated Statements of Comprehensive HTML 29K Loss 19: R6 Condensed Consolidated Statements of Stockholders' HTML 80K Equity 20: R7 Condensed Consolidated Statements of Cash Flows HTML 84K 21: R8 General Organization and Business HTML 29K 22: R9 Summary of Significant Accounting Policies HTML 143K 23: R10 Cash Equivalents and Short-Term Investments HTML 108K 24: R11 Balance Sheet Components HTML 37K 25: R12 Stockholders' Equity HTML 30K 26: R13 Stock Based Compensation HTML 71K 27: R14 Licenses and Agreements HTML 38K 28: R15 Legal Proceedings HTML 37K 29: R16 Leases HTML 141K 30: R17 Related Party Transactions HTML 22K 31: R18 Subsequent Event HTML 21K 32: R19 Summary of Significant Accounting Policies HTML 173K (Policies) 33: R20 Summary of Significant Accounting Policies HTML 127K (Tables) 34: R21 Cash Equivalents and Short-Term Investments HTML 108K (Tables) 35: R22 Balance Sheet Components (Tables) HTML 36K 36: R23 Stock Based Compensation (Tables) HTML 64K 37: R24 Leases (Tables) HTML 129K 38: R25 General Organization and Business (Details) HTML 44K 39: R26 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash, HTML 38K Cash equivalents and Restricted Cash (Details) 40: R27 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Loss HTML 28K per share (Details) 41: R28 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair HTML 25K value (Details) 42: R29 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 23K Stock-based compensation expense (Details) 43: R30 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 23K Stock-based compensation by instrument (Details) 44: R31 Cash Equivalents and Short-Term Investments HTML 26K (Details) 45: R32 Cash Equivalents and Short-Term Investments - HTML 23K Short-term investments (Details) 46: R33 CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS - Cost HTML 33K and fair value (Details) 47: R34 Balance Sheet Components (Details) HTML 34K 48: R35 Stockholders' Equity (Details) HTML 90K 49: R36 STOCK BASED COMPENSATION - Stock Options (Details) HTML 59K 50: R37 STOCK BASED COMPENSATION - Assumptions (Details) HTML 31K 51: R38 STOCK BASED COMPENSATION - Additional information HTML 104K (Details) 52: R39 Licenses and Agreements (Details) HTML 69K 53: R40 Legal Proceedings (Details) HTML 51K 54: R41 LEASES - Company's right-of-use asset and lease HTML 28K liabilities (Details) 55: R42 LEASES - components of lease expenses (Details) HTML 42K 56: R43 LEASES - maturities of the Company's operating HTML 45K lease liabilities (Details) 57: R44 LEASES - Additional information (Details) HTML 142K 58: R45 RELATED PARTY TRANSACTIONS - Additional HTML 35K information (Details) 59: R46 Subsequent Event (Details) HTML 23K 61: XML IDEA XML File -- Filing Summary XML 106K 13: XML XBRL Instance -- iova-20200630x10q_htm XML 1.90M 60: EXCEL IDEA Workbook of Financial Reports XLSX 88K 9: EX-101.CAL XBRL Calculations -- iova-20200630_cal XML 113K 10: EX-101.DEF XBRL Definitions -- iova-20200630_def XML 491K 11: EX-101.LAB XBRL Labels -- iova-20200630_lab XML 881K 12: EX-101.PRE XBRL Presentations -- iova-20200630_pre XML 744K 8: EX-101.SCH XBRL Schema -- iova-20200630 XSD 133K 62: JSON XBRL Instance as JSON Data -- MetaLinks 254± 388K 63: ZIP XBRL Zipped Folder -- 0001104659-20-091526-xbrl Zip 351K
|
This ‘10-Q’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 8/6/20 | 8-K | ||
For Period end: | 6/30/20 | |||
12/31/19 | 10-K | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/28/24 Iovance Biotherapeutics, Inc. 10-K 12/31/23 95:11M Toppan Merrill Bridge/FA 2/28/23 Iovance Biotherapeutics, Inc. 10-K 12/31/22 78:10M Toppan Merrill Bridge/FA 2/24/22 Iovance Biotherapeutics, Inc. 10-K 12/31/21 79:10M Toppan Merrill Bridge/FA 2/25/21 Iovance Biotherapeutics, Inc. 10-K 12/31/20 84:11M Toppan Merrill Bridge/FA 2/09/21 Iovance Biotherapeutics, Inc. 424B5 1:799K Toppan Merrill/FA 11/05/20 Iovance Biotherapeutics, Inc. 10-Q 9/30/20 62:7.8M Toppan Merrill Bridge/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/09/20 Iovance Biotherapeutics, Inc. 8-K:5,9 6/08/20 12:480K Toppan Merrill/FA 5/27/20 Iovance Biotherapeutics, Inc. 8-K:5,8,9 5/27/20 12:508K Toppan Merrill/FA 2/25/20 Iovance Biotherapeutics, Inc. 10-K 12/31/19 88:11M Toppan Merrill/FA |